QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NASDAQ:CDTX

Cidara Therapeutics - CDTX Price Target & Analyst Ratings

$1.23
+0.02 (+1.65%)
(As of 01/31/2023 05:32 PM ET)
Add
Compare
Today's Range
$1.17
$1.26
50-Day Range
$0.48
$1.38
52-Week Range
$0.40
$1.60
Volume
1.31 million shs
Average Volume
2.84 million shs
Market Capitalization
$88.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25

Cidara Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 3 Analyst Ratings

Consensus Analyst Price Target

$6.25
408.13% Upside
High Prediction$6.50
Average Prediction$6.25
Low Prediction$6.00
TypeCurrent
1/31/22 to 1/31/23
1 Month Ago
1/1/22 to 1/1/23
3 Months Ago
11/2/21 to 11/2/22
1 Year Ago
1/31/21 to 1/31/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
3 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$6.25$6.00$6.00$6.56
Predicted Upside408.13% Upside804.98% Upside473.34% Upside258.61% Upside
Get Cidara Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.


CDTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CDTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cidara Therapeutics Stock vs. The Competition

TypeCidara TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.64
2.46
Consensus RatingBuyBuyHold
Predicted Upside425.08% Upside948.90% Upside10.22% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/25/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$6.00 ➝ $6.50+407.81%
3/16/2022Aegis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Weinstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
3/8/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joseph Stringer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$6.00+760.82%
12/16/2021Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$5.00 ➝ $6.00+331.65%
9/22/2021WBB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeBuy ➝ Strong-Buy$6.25+192.06%
11/6/2020Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jason McCarthy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$10.00+331.03%
8/26/2020Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$6.00 ➝ $5.00+37.36%
8/13/2020Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$6.00+58.73%
(Data available from 1/31/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CDTX Price Target - Frequently Asked Questions

What is Cidara Therapeutics's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Cidara Therapeutics stock is Buy based on the current 3 buy ratings for CDTX. The average twelve-month price prediction for Cidara Therapeutics is $6.25 with a high price target of $6.50 and a low price target of $6.00. Learn more on CDTX's analyst rating history.

Do Wall Street analysts like Cidara Therapeutics more than its competitors?

Analysts like Cidara Therapeutics more than other Medical companies. The consensus rating score for Cidara Therapeutics is 3.00 while the average consensus rating score for medical companies is 2.65. Learn more on how CDTX compares to other companies.

Does Cidara Therapeutics's stock price have much upside?

According to analysts, Cidara Therapeutics's stock has a predicted upside of 532.27% based on their 12-month price targets.

What analysts cover Cidara Therapeutics?

Cidara Therapeutics has been rated by HC Wainwright in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:CDTX) was last updated on 1/31/2023 by MarketBeat.com Staff